Which medications in the drug class Acetylcholinesterase Inhibitors, Central are used in the treatment of Parkinson Disease?

Updated: Jan 24, 2019
  • Author: Robert A Hauser, MD, MBA; Chief Editor: Selim R Benbadis, MD  more...
  • Print
Answer

Acetylcholinesterase Inhibitors, Central

Pathologic changes in dementia associated with PD involve cholinergic neuronal pathways that project from the basal forebrain to the cerebral cortex and hippocampus. These pathways may be involved in memory, attention, learning, and other cognitive processes. Acetylcholinesterase inhibitors may exert their therapeutic effect by enhancing cholinergic function through inhibition of acetylcholinesterase.

Donepezil (Aricept)

Donepezil is a reversible inhibitor of ACh and exerts its beneficial effects by enhancing cholinergic function. It is indicated for the treatment for dementia of the Alzheimer type.

Rivastigmine (Exelon)

Rivastigmine is indicated for the treatment of mild to moderate dementia associated with PD. In addition, it is also approved for the treatment of mild to moderate dementia of the Alzheimer type.

Rivastigmine is a selective, competitive, and reversible acetylcholinesterase (ACh) inhibitor. It may reversibly inhibit cholinesterase, which may, in turn, increase concentrations of ACh available for synaptic transmission in CNS and thereby enhance cholinergic function. The effect may lessen as the disease process advances and fewer cholinergic neurons remain functionally intact. It is available as a capsule and an extended-release transdermal.

Galantamine (Razadyne, Razadyne ER)

Galantamine is a competitive and reversible inhibitor of ACh. It is approved for the treatment of mild to moderate dementia of the Alzheimer type.


Did this answer your question?
Additional feedback? (Optional)
Thank you for your feedback!